Rottapharm Biotech: POC in osteoarthritis pain
Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1462 entries already.
Entries by Thomas Gabrielczyk
Creoptix AG closes CHF8m financing round
/in News/by Thomas GabrielczykSwiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.
AMR: GARDP and Entasis Therapeutics start pivotal study
/in News/by Thomas GabrielczykEntasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority […]
BASF broadens biotech business by Isobionics acquisition
/in News/by Thomas GabrielczykBASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.
Gut bacterial enzyme keeps inflammation away
/in News/by Thomas GabrielczykAn antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections.
Tacalyx GmbH raises 7m in seed funding
/in News/by Thomas GabrielczykGerman Tacalyx GmbH has baged 7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans.
EMA greenlights new medicines
/in News/by Thomas GabrielczykAt its September meeting, the EMAs CHMP recommended three innovative medicines for EU market approval.
New malaria lead kills 99.9% of pathogens
/in News/by Thomas GabrielczykDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
/in News/by Thomas GabrielczykSwiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.